We are live on ! Find out more
BXC icon

BlueLinx

156 hedge funds and large institutions have $521M invested in BlueLinx in 2022 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 62 increasing their positions, 49 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more funds holding in top 10

Funds holding in top 10: 68 (+2)

27% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 49

7% more call options, than puts

Call options by funds: $14M | Put options by funds: $13.1M

0.04% less ownership

Funds ownership: 80.85%80.81% (-0.04%)

7% less first-time investments, than exits

New positions opened: 28 | Existing positions closed: 30

4% less funds holding

Funds holding: 163156 (-7)

8% less capital invested

Capital invested by funds: $567M → $521M (-$45.7M)

Holders
156
Holders Change
-7
Holders Change %
-4.29%
% of All Funds
2.63%
Holding in Top 10
8
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+33.33%
% of All Funds
0.13%
New
28
Increased
62
Reduced
49
Closed
30
Calls
$14M
Puts
$13.1M
Net Calls
+$878K
Net Calls Change
+$16.3M
Name Holding Trade Value Shares
Change
Change in
Stake
AIM
26
Artemis Investment Management
United Kingdom
$4.96M +$1.01M +13,392 +22%
HIM
27
Hillsdale Investment Management
Ontario, Canada
$4.86M -$860K -11,450 -14%
SG Americas Securities
28
SG Americas Securities
New York
$4.74M +$5.33M +70,955 New
QC
29
Quantedge Capital
Singapore
$4.58M +$210K +2,800 +4%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$4.57M -$517K -6,877 -9%
GC
31
Globeflex Capital
California
$4.56M +$996K +13,256 +24%
FG
32
Formula Growth
Quebec, Canada
$4.25M +$752K +10,009 +19%
DA
33
Denali Advisors
California
$3.46M +$1.66M +22,107 +74%
Renaissance Technologies
34
Renaissance Technologies
New York
$3.44M +$1.67M +22,200 +76%
Jacobs Levy Equity Management
35
Jacobs Levy Equity Management
New Jersey
$3.14M -$1.8M -24,005 -34%
CAM
36
ClariVest Asset Management
California
$2.93M -$709K -9,441 -18%
Millennium Management
37
Millennium Management
New York
$2.89M -$9.64M -128,357 -75%
PAM
38
Panagora Asset Management
Massachusetts
$2.81M +$1.39M +18,465 +78%
Morgan Stanley
39
Morgan Stanley
New York
$2.74M +$334K +4,439 +12%
Invesco
40
Invesco
Georgia
$2.74M +$1.01M +13,465 +49%
AQR Capital Management
41
AQR Capital Management
Connecticut
$2.74M +$1.65M +21,970 +116%
D.E. Shaw & Co
42
D.E. Shaw & Co
New York
$2.54M +$1.88M +24,985 +191%
HAI
43
Hennessy Advisors Inc
California
$2.44M +$255K +3,400 +10%
TI
44
Trexquant Investment
Connecticut
$1.99M +$1.78M +23,706 +390%
Stifel Financial
45
Stifel Financial
Missouri
$1.98M +$2.23M +29,687 New
BCM
46
Bridgeway Capital Management
Texas
$1.84M
APP
47
Alpha Paradigm Partners
Illinois
$1.81M +$2.04M +27,110 New
New York State Common Retirement Fund
48
New York State Common Retirement Fund
New York
$1.77M +$615K +8,179 +44%
Mariner
49
Mariner
Kansas
$1.73M -$96.3K -1,282 -5%
Charles Schwab
50
Charles Schwab
California
$1.63M +$3.23K +43 +0.2%

BXC Hedge Fund Activity: Q2 2022 in Review

156 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in BlueLinx (BXC) for Q2 2022, worth a combined $521M — down 8.1% from $567M a quarter earlier.

Sellers outnumbered buyers: 30 funds closed out of BXC and 28 opened new positions — a net loss of 2 holders — while 49 trimmed existing stakes and 62 added.

The largest buyer was JP Morgan Chase, adding an estimated $11.5M. The largest seller was Driehaus Capital Management, exiting entirely with an estimated $12.1M sold.

  • 156 institutional investors held BlueLinx (BXC) as of Q2 2022, down from 163 in Q1 2022.
  • Funds reported $521M of BlueLinx stock for Q2 2022, down 8.1% quarter-over-quarter.
  • 28 funds opened new BlueLinx positions in Q2 2022 and 30 closed out, a net change of -2 holders.
  • The largest BlueLinx buyer in Q2 2022 was JP Morgan Chase, an estimated $11.5M added.
  • The largest BlueLinx seller in Q2 2022 was Driehaus Capital Management, an estimated $12.1M sold.

Based on aggregated 13F filings for Q2 2022.